

# PRECEPTORSHIP PROGRAMME

## NSCLC

Standards of care, evolving  
paradigm and future  
perspectives

**ESMO VIRTUAL  
PRECEPTORSHIP**

**6-8 MAY 2021**

**Co-Chairs**

Pasi A. Jänne, United States  
Tony S. K. Mok, Hong Kong  
Solange Peters, Switzerland

# ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

## NSCLC

Standards of care, evolving paradigm and future perspectives

6-7-8 MAY 2021

---

**CO-CHAIRS:** Pasi A. Jänne, United States  
Tony S. K. Mok, Hong Kong  
Solange Peters, Switzerland

**SPEAKERS:** Lukas Bubendorf, Switzerland  
Linda Coate, Ireland  
Anne-Marie Dingemans, Netherlands  
Kevin Franks, United Kingdom  
Tetsuya Mitsudomi, Japan  
Keunchil Park, South Korea  
David Planchard, France  
Ben Solomon, Australia  
Daniel S. W. Tan, Singapore  
Giulia Veronesi, Italy

---

### LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology and histo-prognostic, molecular factors, and liquid biopsies in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC and obtain some highlights of ongoing clinical research

---

### ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

**AstraZeneca** 

---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



All timings are to be considered GMT+8 (Singapore Local Time)

## Thursday, 6 May 2021

<b>15:00-15:10</b> 10'	<b>Welcome</b>	<b>Tony S. K. Mok, HK</b> <b>Solange Peters, CH</b>
10'	Introduction and Objectives	
<b>15:10-16:25</b> 75'	<b>SESSION 1</b> <b>Screening, diagnosis and staging</b>	<b>Chair/Moderator:</b> <b>Solange Peters, CH</b>
20'	Lung cancer screening: efficacy and cost-effectiveness	Linda Coate, IE
20'	The role of pathology and genetic/molecular analyses	Lukas Bubendorf, CH
20'	Staging investigations at diagnosis	Giulia Veronesi, IT
15'	Discussion	Faculty
<b>16:25-16:35</b>	<b>Break</b>	
<b>16:35-17:30</b> 55'	<b>SESSION 2</b> <b>Adjuvant therapy</b>	<b>Chair/Moderator:</b> <b>Tony S. K. Mok, HK</b>
20'	Adjuvant/Neo-adjuvant chemotherapy and radiotherapy strategies for resected NSCLC	Anne-Marie Dingemans, NL
20'	Adjuvant and neo-adjuvant targeted and immunotherapeutic agents: clinical evidence and clinical research	Daniel S. W. Tan, SG
15'	Discussion	Faculty
<b>17:30-18:10</b> 40'	<b>SESSION 3</b> <b>Multi-disciplinary lung tumour board</b>	<b>Chair/Moderator:</b> <b>Pasi A. Jänne, US</b>
40'	Management of stage III - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Tetsuya Mitsudomi, JP Kevin Franks, UK Anne-Marie Dingemans, NL Faculty

## Friday, 7 May 2021

<b>15:00-15:40</b> 40'	<b>SESSION 4</b> <b>Multi-disciplinary lung tumour board</b>	<b>Chair/Moderator:</b> <b>Solange Peters, CH</b>
40'	Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Tetsuya Mitsudomi, JP Kevin Franks, UK Tony S. K. Mok, HK Faculty
<b>15:40-16:40</b> 60'	<b>SESSION 5</b> <b>Audience cases</b>	<b>Chair/Moderator:</b> <b>Tony S. K. Mok, HK</b>
60'	Participants clinical case discussion (6x10')	Faculty
<b>16:40-16:50</b>	<b>Break</b>	

<b>16:50-17:45</b> 55'	<b>SESSION 6</b> <b>Systemic therapy for advanced NSCLC</b>	<b>Chair/Moderator:</b> <b>Tony S. K. Mok, HK</b>
20'	Immune Checkpoint Inhibitors as a consolidation in stage III NSCLC	Keunchil Park, KR
20'	Immune Checkpoint Inhibitors across lines of metastatic NSCLC	Solange Peters, CH
15'	Discussion	Faculty

## Saturday, 8 May 2021

<b>15:00-16:55</b> 115'	<b>SESSION 7</b> <b>Targeted therapies</b>	<b>Chair/Moderator:</b> <b>Solange Peters, CH</b>
20'	Systemic therapy for non-oncogene addicted NSCLC	David Planchard, FR
20'	New treatment options for EGFR-mutated NSCLC	Tony S. K. Mok, HK
20'	New treatment options for ALK-rearranged NSCLC	Ben Solomon, AU
20'	KRAS mutant NSCLC	Pasi A. Jänne, US
20'	ROS1/RET/TRK/BRAF/MET	Ben Solomon, AU
15'	Discussion	Faculty

<b>16:55-17:05</b>	<b>Break</b>	
--------------------	--------------	--

<b>17:05-17:35</b> 30'	<b>SESSION 8</b> <b>Audience cases</b>	<b>Chair/Moderator:</b> <b>Tony S. K. Mok, HK</b>
30'	Participants clinical case discussion (3x10')	Faculty

<b>17:35-18:50</b> 75'	<b>SESSION 9</b> <b>Other thoracic tumours and molecular testing</b>	<b>Chair/Moderator:</b> <b>Pasi A. Jänne, US</b>
20'	Optimal platform and sequence for biomarker testing in advanced NSCLC: IHC, PCR, NGS and more	Lukas Bubendorf, CH
20'	Prognostic and predictive biomarkers for immune-oncology: current state and research	Solange Peters, CH
20'	Liquid biopsy applications in the management of NSCLC patients	David Planchard, FR
15'	Discussion	Faculty

<b>18:50-19:00</b> 10'	<b>Conclusion and take home messages</b>	<b>Pasi A. Jänne, US</b> <b>Tony S. K. Mok, HK</b> <b>Solange Peters, CH</b>
---------------------------	--	--

**Note:** Each 10' min slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion